Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: A phase II multicenter study by the Hellenic Cooperative Oncology Group

Annals of Oncology

Volumn 16, Issue 5, 2005, Pages 773-779

  Xiros, N ^a   Papacostas, P ^b   Economopoulos, T ^a   Samelis, G ^b   Efstathiou, E ^a   Kastritis, E ^a   Kalofonos, H ^c   Onyenadum, A ^c   Skarlos, D ^d   Bamias, A ^e   Gogas, H ^a   Bafaloukos, D ^f   Samantas, E ^g   Kosmidis, P ^h  

^a UNIVERSITY OF ATHENS   (Greece)

^b Ippokration Hospital Thessaloniki   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

^d 'Henry Dynan' Hospital   (Greece)

^e UNIVERSITY OF IOANNINA   (Greece)

^f METROPOLITAN HOSPITAL   (Greece)

^g AGII ANARGIRI CANCER HOSPITAL   (Greece)

^h HYGEIA HOSPITAL   (Greece)

Author keywords

Carboplatin; Gemcitabine; Pancreatic cancer

Indexed keywords

CARBOPLATIN; CORTICOSTEROID; FENTANYL; GEMCITABINE; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PAIN; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; INFECTION; LIVER TOXICITY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PANCREAS CANCER; PRIORITY JOURNAL; STOMATITIS; SURVIVAL TIME; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GREECE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TERMINALLY ILL; TREATMENT OUTCOME;

EID: 20044395778     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi160     Document Type: Article

References (31)

1. Glimelius B. Pancreatic and hepatobiliary cancers: adjuvant therapy and management of inoperable disease. Ann Oncol 2000; 11 (Suppl 3): 153-159.
2. Van Cutsem E, Haustermans K, Van Steenbergen W. New treatment possibilities for pancreatic and biliary tumors. Ann Oncol 2000; 11 (Suppl 3): 165-169.
3. Kroep J, Pinedo H, Groeningen C et al. Experimental drugs and drug combinations in pancreatic cancer. Ann Oncol 1999; 10 (Suppl 4): 234-238.
4. Rougier P, Ducreux M, Douillard J et al. Efficacy of 5-FU + cisplatin compared to bolus 5-FU in advanced pancreatic carcinoma: a randomized trial from the France Anticancer Centers Digestive Group. Proc Am Soc Clin Oncol 1999; 18: 274a.
5. André T, Loty J, Boulec C et al. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann Oncol 1996; 7: 173-178.
6. Abbruzzese J. Phase I studies with the novel nucleoside analog gemcitabine. Semin Oncol 1996; 23: 25-31.
7. Casper ES, Green MR, Kelsen DP et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34.
8. Carmichael J, Fink U, Rossl RCG et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73: 101-105.
9. Burris H, Moore M, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomised study. J Clin Oncol 1997; 15: 2403-2413.
10. Storniolo A, Enas N, Brown C et al. AD investigational new drug treatment program for patients with gemcitabine. Results for over 3000 patients with pancreatic carcinoma. Cancer 1990; 85: 1261-1268.
11. Van Riel J, Van Groeningen C, Pinedo H et al. Current chemotherapy possibilities in pancreaticobiliary cancer. Ann Oncol 1999; 10 (Suppl 4): 157-161.
12. Scher R, Kosierowsky R, Lusch C et al. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs 1996; 13: 347-354.
13. Wagener D, Verdonk H, Dirix L et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995; 6: 129-132.
14. Pazdur R, Meropol N, Casper E et al. Phase II trial of ZD1964 (Tomudex) in patients with advanced pancreatic cancer. Invest New Drugs 1996; 13: 355-358.
15. Moore M, Feld R, Hedley D et al. A phase II study of temozolamide in advanced untreated pancreatic cancer. Invest New Drugs 1998; 16: 77-79.
16. Androulakis N, Kourousis C, Dimopoulos M et al. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 1999; 17: 1779-1785.
17. Abruzzese JL, Evans D, Gravel D et al. Docetaxel a potentially active agent for patients with pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1995; 15: 107a.
18. Okada S, Sakata Y, Matson S et al. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Br J cancer 1999; 80: 438-443.
19. Mavroudis D, Kourousis C, Kakolyris S et al. Phase I study of gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report. Semin Oncol 2000; 1 (Suppl 2): 25-30.
20. Whitehead R, Jacobson J, Brown T et al. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic cancer: a Southwest Oncology Group Study. J Clin Oncol 1997; 15: 2414-2419.
21. Cascinu S, Silva R, Barni S et al. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group of Digestive Tract Cancer (GISCAD). Br J Cancer 1999; 80: 1595-1598.
22. Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
23. Heinemann V. Gemcitabine-based combination treatment of pancreatic cancer. Semin Oncol 2002; 29: 25-35.
24. Berling JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-3275.
25. Van Cutsem E, van de Velde H, Karasek H et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438.
26. Stathopoulos GP, Rigatos SK, Dimopoulos M-A et al. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2003; 14: 388-394.
27. Stathopoulos GP, Mavroudis D, Tsavaris N et al. Treatment of pancreatic cancer with combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2001; 12: 101-103.
28. Alberts SR, Townley PM, Goldberg RM et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol 2003; 14: 580-585.
29. Feliu J, Mel R, Borrega P et al. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. Ann Oncol 2002; 13: 1756-1762.
30. Scheithauer W, Schüll B, Ulrich-Pur H et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 2003; 14: 97-104.
31. Heinemann V, Wilke H, Mergenthaler HG et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399-1403.